Bevacizumab for Central Retinal Vein Occlusion Study

Anders Kvanta60 enrolled

Overview

Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity. The present study intends to investigate if intravitreal bevacizumab can improve visual acuity as compared to sham-treated control patients.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

QUADRUPLE

Enrollment

Conditions

Central Retinal Vein Occlusion

Interventions

bevacizumabDRUG

Intravitreal injection of 1.25 mg bevacizumab

Sham bevacizumab injectionDRUG

Sham intravitreal injection

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * CRVO with duration \< 6 months * Visual acuity of 20/800 to 20/50 Exclusion Criteria: * CRVO with duration of \> 6 months * previous treatment with anti-angiogenic drugs

Locations (1)

St Eriks Eye Hospital

Stockholm, Sweden

Outcomes

Primary Outcomes

The proportion of patients gaining 15 ETDRS letters or more

Time frame: 6 months

Secondary Outcomes

Change in foveal thickness

Time frame: 6 months

Cases of neovascular glaucoma

Time frame: 6 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.